title: [Incidence, investigation and long-term follow-up of macroscopic hematuria in patients treated with non vitamin K antagonist oral anticoagulant: Insight from a specialist cardiology clinic].
abstract: Incidence, investigation and long-term follow-up of macroscopic hematuria in patients treated with non vitamin K antagonist oral anticoagulant: Insight from a specialist cardiology clinic In a retrospective long-term follow up of patients with non-valvular atrial fibrillation treated with non-vitamin K dependent oral anticoagulants in a specialist clinic, the incidence of reported macroscopic hematuria was relatively low and none of these was major bleeding. Urgent investigation of the bleeding source by a urologist showed different etiologies, like newly discovered neoplasm, benign hyperplasia of the prostate gland, renal stones, or inflammatory changes in the urinary bladder, and some had normal findings. The majority of patients continued oral anticoagulation therapy after investigation. Incidence of re-bleeding was very low.
authors.affiliation: Stockholm Heart Center - Stockholm, Sweden Stockholm Heart Center - Stockholm, Sweden.
authors.forename: Faris
authors.initials: F
authors.lastname: Al Khalili
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000008:administration & dosage* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D000069604:Dabigatran / Q000008:administration & dosage* / Q000627:therapeutic use; D057915:Drug Substitution; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006417:Hematuria / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007669:Kidney Calculi / Q000150:complications; D008297:Male; D009369:Neoplasms / Q000150:complications; D011470:Prostatic Hyperplasia / Q000150:complications; D011720:Pyrazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D011728:Pyridones / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000991:Antithrombins; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran